Genetic interaction of  P2X 7   receptor and  VEGFR-2  polymorphisms identifies a favorable prognostic profile in prostate cancer patients

Anna Solini; Vittorio Simeon; Lisa Derosa; Paola Orlandi; Chiara Rossi; Andrea Fontana; Luca Galli; Teresa Di Desidero; Anna Fioravanti; Sara Lucchesi; Luigi Coltelli; Laura Ginocchi; Giacomo Allegrini; Romano Danesi; Alfredo Falcone; Guido Bocci

doi:10.18632/oncotarget.4926

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Genetic interaction of P2X₇ receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients

Anna Solini, Vittorio Simeon, Lisa Derosa, Paola Orlandi, Chiara Rossi, Andrea Fontana, Luca Galli, Teresa Di Desidero, Anna Fioravanti, Sara Lucchesi, Luigi Coltelli, Laura Ginocchi, Giacomo Allegrini, Romano Danesi, Alfredo Falcone and Guido Bocci _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:28743-28754. https://doi.org/10.18632/oncotarget.4926

Metrics: PDF 2386 views | HTML 3022 views | ?

Abstract

Anna Solini1, Vittorio Simeon2, Lisa Derosa3, Paola Orlandi1, Chiara Rossi1, Andrea Fontana3, Luca Galli3, Teresa Di Desidero1, Anna Fioravanti1, Sara Lucchesi4, Luigi Coltelli4, Laura Ginocchi4, Giacomo Allegrini4, Romano Danesi1, Alfredo Falcone3, Guido Bocci1

1Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

2Laboratory of Pre-clinical and Translational Research, IRCCS - CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Potenza, Italy

3Oncology Unit 2, University Hospital of Pisa, Pisa, Italy

4Division of Medical Oncology, Pontedera Hospital, Azienda USL of Pisa, Pontedera, Italy

Correspondence to:

Guido Bocci, e-mail: [email protected]

Keywords: survival dimensionality reduction analysis, P2X7 receptor, VEGFR-2, polymorphisms, prostate cancer

Received: April 07, 2015 Accepted: August 10, 2015 Published: August 21, 2015

ABSTRACT

VEGFR-2 and P2X₇ receptor (P2X₇R) have been described to stimulate the angiogenesis and inflammatory processes of prostate cancer. The present study has been performed to investigate the genetic interactions among VEGFR-2 and P2X₇R SNPs and their correlation with overall survival (OS) in a population of metastatic prostate cancer patients. Analyses were performed on germline DNA obtained from blood samples and SNPs were investigated by real-time PCR technique. The survival dimensionality reduction (SDR) methodology was applied to investigate the genetic interaction between SNPs. One hundred patients were enrolled. The SDR software provided two genetic interaction profiles consisting of the combination between specific VEGFR-2 (rs2071559, rs11133360) and P2X₇R (rs3751143, rs208294) genotypes. The median OS was 126 months (95% CI, 115.94–152.96) and 65.65 months (95% CI, 52.95–76.53) for the favorable and the unfavorable genetic profile, respectively (p < 0.0001). The genetic statistical interaction between VEGFR-2 (rs2071559, rs11133360) and P2X₇R (rs3751143, rs208294) genotypes may identify a population of prostate cancer patients with a better prognosis.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4926

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Genetic interaction of P2X₇ receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients

Abstract

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients

Abstract

Genetic interaction of P2X₇ receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients